Cytidine deaminases of the APOBEC family (ApoB mRNA editing catalytic subunit) generate targeted damage in nucleic acids by deaminating cytosins to uracils. The catalytically active family members are APOBEC1, APOBEC3 proteins (which comprise APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H) and activation-induced deaminase (AID) (reviewed in Conticello1, 2). APOBEC1 deaminates the mRNA for Apolipoprotein B thereby generating ApoB48, which mediates the absorption of dietary lipid from the intestine.3 Whereas APOBEC3 proteins are implicated in the natural defense against retroviruses and mobile elements by mutating and thereby inactivating retroviral single stranded DNA intermediates, AID mediates somatic hypermutation and class switch recombination of immunoglobulin genes in B cells.4 As it was shown that AID can cause substantial off-target DNA damage, AID has been implicated in B-cell lymphomagenesis by mutating oncogenes and by mediating chromosomal translocations as side product of aberrant class switch recombination.5 In chronic lymphocytic leukemia (CLL), previous reports have described the presence of AID transcripts in a subset of CLL patients where AID-expressing CLL patients exhibited a significantly decreased time to treatment and overall survival.6 Paradoxically, AID levels were higher in CLL cells expressing unmutated immunoglobulin variable domains (IgV-UM) encoding the B-cell antigen receptor, which predicts for poor prognosis, whereas CLL cells with somatically hypermutated IgV (IgV-Mut) tend to have lower AID transcript abundances.7 Also, AID expression associates with complex genomic aberrations and with Richter’s transformation to a more aggressive disease,8 providing strong evidence that AID is implicated in clonal evolution and pathogenesis in CLL. However, recent studies have revealed that other APOBEC family members are as well implicated in cancer development by inducing genome wide C>U deaminations that turn to C>T transition mutations after DNA replication.9 It was found that APOBEC-mediated mutations can lead to mutation showers (termed kataegis) in which multiple mutations are spaced by only one to several hundred nucleotides.10
In CLL, kataegic events were recently described that exhibit a signature of AID-mediated hypermutation.11 These clustered mutations are mostly but not exclusively found within the Ig locus and are restricted to IgV-Mut CLL cases.11 To compare clustered mutations inside and outside the Ig locus, we reanalyzed CLL whole genome sequencing data from Puente and coworkers, who sequenced two IgV-UM and two IgV-Mut CLL samples (Supplementary Table 6 from Puente et al.12). We thereby found that genome-wide mutations had a mean intermutational distance from 2.8 Mb (95% confidence interval: 2.698–2.937 Mb), which was similar for IgV-Mut and IgV-UM samples (Figure 1a). By searching for clustered mutations with intermutational distances below 10 kb, we noticed that while the two IgV-UM samples did not harbor mutation foci (defined as ⩾3 mutations each spaced by ⩽10 kb), the two IgV-Mut samples exhibited 19 clusters with a total of 113 (5.4% of total) mutations where ⩾3 mutations were spaced with an intermutational distance below 10 kb (Figure 1a). From these clusters, 49 mutations (43%) were located within the Ig locus and 64 (57%) were located outside the Ig locus (Figure 1a and Supplementary Table 1). In contrast to kataegis described in breast cancer,11 the clustered mutations found in CLL do not have a particular bias toward C>T or C>G mutations, neither at Ig nor at non-Ig clusters Supplementary Table 1), but rather have a mutation feature typical for somatic hypermutation where AID-mediated cytidine deamination is processed by error prone polymerases.4, 11 In line with this, C>T transitions within clustered mutations at the Ig loci were confined to the AID hot spot motif WRCY (W=A or T; R=A or G; Y=C or T; Figure 1c). In contrast, C>T transitions at mutation clusters outside the Ig locus were primarily found at TCW motifs, which is no AID but an APOBEC3 mutation motif (Figure 1c).10 Genome-wide unclustered C>T mutations outside mutation foci did not show a certain motif bias, neither when all CpGs or CpG islands were excluded from the analysis, as methylated cytosines (which are confined to CpG dinucleotides) are more prone to spontaneous deamination than normal cytosines13 (Figure 1b). Apart from the APOBEC3 motif at C>T transitions within clustered mutations at non-Ig loci, the spectrum of mutations was quite similar to hypermutation at Ig loci, with no apparent sequence bias (Supplementary Table 1). Thus, it is tempting to speculate that in CLL, APOBEC3 might operate in combination with factors of the hypermutation machinery to induce off-target DNA damage at non-Ig loci.
As our mutation analysis revealed that C>T transitions within small mutation clusters occur at APOBEC3 recognition motifs outside the Ig loci in CLL, we next asked whether any APOBEC members are expressed in CLL samples. We therefore measured transcript levels of catalytically active members APOBEC3A to APOBEC3H using SYBR green quantitative reverse transcription (qRT)-PCR in a set of 10 IgV-Mut and 8 IgV-UM CLL samples and compared values with that from purified B cells of 5 healthy controls. As shown in Figure 2a, we found that APOBEC3A, APOBEC3B and APOBEC3H were expressed in CLL samples with a slight upregulation compared with healthy controls (Figure 2a). In addition, we observed a slight but significant difference in APOBEC3A, APOBEC3B and APOBEC3H expression values between IgV-Mut or IgV-UM samples (APOBEC3A: median 2.87 vs 1.92, P=0.016; APOBEC3B: median 1.37 vs 0.82, P=0.034; APOBEC3H: median 4.66 vs 2.77, P=0.021; Figure 2a). We subsequently tested protein expression of APOBEC3A, APOBEC3B and APOBEC3H by immunoblotting and found bands corresponding to APOBEC3A and APOBEC3B in almost any CLL sample irrespective of IgV mutation status (Figure 2b). Although median expression values of APOBEC3A and APOBEC3B were 1.5 and 1.7 times higher in IgV-Mut compared with IgV-UM CLL samples in qRT-PCR, this difference was too small to be discerned in immunoblotting on the level of protein. APOBEC3H, albeit showing highest expression in qRT-PCR, did not show detectable protein amounts in immunoblotting. A faint band for APOBEC3H that appeared in MEC1 cell lysates served as positive control (Figure 2b). Upon stimulation of CLL cells with CpG, APOBEC3B protein was upregulated, while APOBEC3A remained quite constant or even showed reduced band intensities in immunoblotting (Figure 2b). The APOBEC member AID was only detectable on in vitro stimulation of cells with CpG before cell lysis in one IgV-Mut and one IgV-UM sample, respectively (Figure 2b).
Overall, our data show that aside of AID, also APOBEC3 deaminases are likely implicated in mediating off-target mutations in CLL. We show that APOBEC3A and APOBEC3B are more abundant on protein level in CLL than in AID, and clustered genomic C>T mutations outside the Ig locus occur at APOBEC3 hot spot motifs in IgV-Mut CLL. As these clustered mutations were confined to IgV-Mut samples, we initially suspected that APOBEC3 members were differentially expressed according to the IgV mutation status. However, although APOBEC3A, APOBEC3B and APOBEC3H transcripts were significantly lower expressed in IgV-UM samples, it is questionable whether this small difference has biological significance, as APOBEC3A and APOBEC3B were easily detectable on the protein level in both IgV-Mut as well as IgV-UM samples. However, as it was shown that APOBEC3 levels correlate with APOBEC3-induced mutations,14 it is conceivable that even small differences in APOBEC3 expression levels could account for the observed difference in APOBEC3-induced clustered mutations in IgV-Mut vs IgV-UM CLL (Figure 2a). Alternatively, as recent studies have revealed that apart from APOBEC expression additional factors of the DNA repair machinery10 are required for inducing kataegis, our data could suggest that any of these factors are not expressed in IgV-UM samples, similar to the observation that AID expression in IgV-UM CLL samples is not sufficient to diversify IgV genes.7 The absence of any of these factors could either alter the targeting of APOBEC3 to the DNA or otherwise affect the error prone DNA repair of APOBEC3-induced DNA lesions. Hence, it is conceivable that APOBEC3 might operate non-processively in IgV-UM CLL, resulting in the generation of unclustered mutations as opposed to clustered kataegic events in IgV-Mut CLL. From our data we conclude that aside of AID, also APOBEC3 should be considered as a source for genomic mutations in CLL. As CLL has a substantial intraclonal heterogeneity,15 we suspect that ongoing APOBEC3 expression might contribute to this genetic complexity by continuously increasing the mutation load, thereby accelerating clonal evolution to a more aggressive or chemorefractory disease. We further propose that analyzing IgV-Mut vs IgV-UM CLL will likely yield a deeper insight into mechanisms that underlie the initiation of APOBEC3-mediated clustered vs unclustered DNA mutations in cancer in general.
Conticello SG . Creative deaminases, self-inflicted damage, and genome evolution. Ann N Y Acad Sci 2012; 1267: 79–85.
Conticello SG . The AID/APOBEC family of nucleic acid mutators. Genome Biol 2008; 9: 6.
Chester A, Scott J, Anant S, Navaratnam N . RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA. Biochim Biophys Acta 2000; 1494: 1–13.
Di Nola JM, Neuberger MS . Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007; 76: 1–22.
Gazumyan A, Bothmer A, Klein IA, Nussenzweig MC, McBride KM . Activation-induced cytidine deaminase in antibody diversification and chromosome translocation. Adv Cancer Res 2012; 113: 167–190.
Patten PEM, Chu CC, Albesiano E, Damle RN, Yan XJ, Kim D et al. IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. Blood 2012; 120: 4802–4811.
Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J et al. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGV(H) gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia 2004; 18: 756–762.
Reiniger L, Bodor C, Bognar A, Balogh Z, Csomor J, Szepesi A et al. Richter’s and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. Leukemia 2006; 20: 1089–1095.
Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013; 494: 366–370.
Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2013; 2: e00534.
Alexandrov LB, Nik-Zainal S, Wedge DC, SAJR Aparicio, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415–421.
Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101–105.
Gonzalgo ML, Jones PA . Mutagenic and epigenetic effects of DNA methylation. Mutat Res 1997; 386: 107–118.
Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013; 45: 970–976.
Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714–726.
This study was supported by the Austrian Science Fund FWF (project P24619 to RGe, Hertha-Firnberg project T516-B13 to NZ), the ‘LIMCR-SCRI GmbH’ and the province of Salzburg.
The authors declare no conflict of interest.
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
About this article
Cite this article
Rebhandl, S., Huemer, M., Gassner, F. et al. APOBEC3 signature mutations in chronic lymphocytic leukemia. Leukemia 28, 1929–1932 (2014). https://doi.org/10.1038/leu.2014.160
This article is cited by
Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator
International Journal of Hematology (2020)
A practical guide for mutational signature analysis in hematological malignancies
Nature Communications (2019)
APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study
Cancer Cell International (2018)
Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation
Cell Communication and Signaling (2017)
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells
British Journal of Cancer (2017)